Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of “Hold” by Analysts

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has earned a consensus rating of “Hold” from the eleven ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $56.8889.

A number of equities analysts recently issued reports on IMCR shares. Jefferies Financial Group started coverage on Immunocore in a report on Monday, August 25th. They issued a “buy” rating and a $48.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Monday, June 2nd. Deutsche Bank Aktiengesellschaft started coverage on Immunocore in a report on Tuesday, May 27th. They issued a “buy” rating and a $65.00 target price on the stock. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 4th. Finally, Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, August 9th.

Immunocore Price Performance

Immunocore stock opened at $33.81 on Friday. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -84.53 and a beta of 0.77. Immunocore has a 52-week low of $23.15 and a 52-week high of $39.33. The stock’s 50 day moving average price is $34.04 and its two-hundred day moving average price is $31.84. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.86 and a current ratio of 5.89.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The firm had revenue of $130.65 million for the quarter, compared to analysts’ expectations of $122.96 million. During the same period in the prior year, the business earned ($0.23) EPS. The company’s revenue for the quarter was up 30.0% compared to the same quarter last year. On average, equities analysts predict that Immunocore will post -0.94 earnings per share for the current year.

Insider Buying and Selling

In related news, insider David M. Berman sold 22,532 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Immunocore

A number of institutional investors and hedge funds have recently bought and sold shares of IMCR. GF Fund Management CO. LTD. purchased a new stake in Immunocore in the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd raised its position in Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after buying an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Immunocore in the 2nd quarter valued at $42,000. Osaic Holdings Inc. raised its position in Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after buying an additional 1,700 shares during the last quarter. Finally, State of Tennessee Department of Treasury purchased a new stake in Immunocore in the 2nd quarter valued at $132,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.